What is Leerink Partnrs’ Forecast for BMY FY2026 Earnings?

Bristol Myers Squibb Company (NYSE:BMY) – Equities researchers at Leerink Partnrs boosted their FY2026 earnings per share estimates for Bristol Myers Squibb in a research note issued on Sunday, November 23rd. Leerink Partnrs analyst D. Risinger now forecasts that the biopharmaceutical company will post earnings of $5.97 per share for the year, up from their prior forecast of $5.89. The consensus estimate for Bristol Myers Squibb’s current full-year earnings is $6.74 per share. Leerink Partnrs also issued estimates for Bristol Myers Squibb’s FY2027 earnings at $6.10 EPS and FY2029 earnings at $5.37 EPS.

Several other equities research analysts also recently commented on BMY. BMO Capital Markets restated a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, November 17th. Daiwa America lowered Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 5th. Daiwa Capital Markets cut Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 target price for the company. in a research report on Tuesday, August 5th. Morgan Stanley reissued a “hold” rating on shares of Bristol Myers Squibb in a research report on Thursday, July 31st. Finally, Scotiabank started coverage on Bristol Myers Squibb in a research report on Thursday, November 13th. They set a “sector perform” rating and a $45.00 price objective for the company. Four analysts have rated the stock with a Buy rating and fifteen have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $54.42.

Bristol Myers Squibb Stock Performance

Shares of BMY opened at $49.33 on Tuesday. The company has a 50-day moving average of $45.43 and a two-hundred day moving average of $46.60. The stock has a market cap of $100.43 billion, a price-to-earnings ratio of 19.89, a PEG ratio of 2.23 and a beta of 0.33. The company has a debt-to-equity ratio of 2.54, a current ratio of 1.21 and a quick ratio of 1.11. Bristol Myers Squibb has a one year low of $42.52 and a one year high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share for the quarter, beating analysts’ consensus estimates of $1.52 by $0.11. The business had revenue of $12.22 billion during the quarter, compared to analyst estimates of $11.75 billion. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.Bristol Myers Squibb’s revenue for the quarter was up 2.8% on a year-over-year basis. During the same quarter last year, the company posted $1.80 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS.

Institutional Investors Weigh In On Bristol Myers Squibb

Several institutional investors and hedge funds have recently modified their holdings of the business. Brighton Jones LLC increased its holdings in shares of Bristol Myers Squibb by 33.4% during the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock valued at $1,116,000 after acquiring an additional 4,935 shares during the last quarter. Mackenzie Financial Corp grew its holdings in Bristol Myers Squibb by 53.7% during the first quarter. Mackenzie Financial Corp now owns 900,576 shares of the biopharmaceutical company’s stock valued at $54,926,000 after purchasing an additional 314,810 shares during the last quarter. Norden Group LLC grew its holdings in Bristol Myers Squibb by 0.8% during the first quarter. Norden Group LLC now owns 92,820 shares of the biopharmaceutical company’s stock valued at $5,661,000 after purchasing an additional 744 shares during the last quarter. Baldwin Investment Management LLC raised its position in shares of Bristol Myers Squibb by 50.4% in the first quarter. Baldwin Investment Management LLC now owns 14,132 shares of the biopharmaceutical company’s stock valued at $862,000 after purchasing an additional 4,733 shares during the period. Finally, Maridea Wealth Management LLC acquired a new stake in shares of Bristol Myers Squibb in the first quarter worth $204,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Insiders Place Their Bets

In other Bristol Myers Squibb news, EVP David V. Elkins sold 56,000 shares of Bristol Myers Squibb stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total value of $2,650,480.00. Following the completion of the sale, the executive vice president directly owned 167,379 shares in the company, valued at $7,922,048.07. The trade was a 25.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.07% of the company’s stock.

Bristol Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, November 3rd. Investors of record on Friday, October 3rd were issued a $0.62 dividend. The ex-dividend date was Friday, October 3rd. This represents a $2.48 dividend on an annualized basis and a yield of 5.0%. Bristol Myers Squibb’s dividend payout ratio is currently 83.78%.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.